InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

GoTHAM: This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy combined with a type of radionuclide therapy or external beam radiation therapy in patients with Merkel Cell Carcinoma that has spread to other parts of the bodyA Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma

Clinical summary


All eligible patients will receive intravenous Avelumab at 10mg/kg every two weeks for 24 months or until unacceptable toxicity or evidence of disease progression. Depending on the group to which they are randomised, enrolled patients will either receive 177-Lu-DOTATATE treatment or external beam radiotherapy on 2 occasions, 8-10 weeks apart.


This trial is treating patients with Merkel Cell Carcinoma


Skin Cancers Skin





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Melanoma and Skin Cancer Trials Limited

Scientific Title

A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma



  • Patient is 18 years of age or older and who has provided written informed consent.
  • Patient has histologically confirmed metastatic MCC.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 .
  • Willing and able to comply with all study protocol requirements for the duration of the study.
  • Patient must have measurable disease by CT or MRI per RECIST version 1.1 criteria.
  • Patient is treatment naïve (no prior systemic therapy for unresectable or metastatic MCC). Note that prior chemotherapy is permitted in the adjuvant setting for loco-regional disease. Prior radiation is permitted for treatment of the primary or loco-regional disease.
  • At least 2 weeks since the completion of prior therapy, including surgery or radiotherapy.
  • Screening laboratory values, obtained within 14 days prior to registration/randomisation must meet the criteria specified in the protocol.
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception
  • WOCBP must have a negative serum or urine pregnancy test within within 7 days prior to the start of avelumab treatment and should be performed every 4 weeks in line with other safety bloods or clinical reviews.
  • Male patients who are sexually active with a WOCBP must use any contraceptive method with a failure rate of less than 1% per year.
  • Patient must be agreeable to have archival tumour material collected


  • Patient is excluded if they have ever had any brain or leptomeningeal metastases.
  • Prior exposure to immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1/PD-L1/PD-L2, etc.) or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Prior exposure to 177Lu-DOTATATE.
  • Prior malignancy within the previous 2 years, except for locally curable cancers that have been apparently cured (e.g. basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, colon, bladder or breast).
  • Life expectancy of 6 months or less.
  • An active, known or suspected autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Current use of immunosuppressive medication, with exceptions detailed in the protocol
  • Prior organ transplantation, including allogeneic stem-cell transplantation.
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Positive test for hepatitis B virus (HBV) surface antigen and/or confirmatory hepatitis C virus (HCV) RNA (if anti-HCV antibody tested positive at Screening).
  • Pregnant or breastfeeding.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
  • Persisting toxicity related to prior therapy (NCI CTCAE v5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgement are acceptable.
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade 3).
  • Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable.
  • Use of any live vaccines against infectious diseases (e.g., influenza, varicella, etc.) within 30 days of registration.


  • Your cancer has spread to other parts of the body.


  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.